Novo and Lundbeck-backed Acacia Pharma previously withdrew plans for a $230m initial public offering on the London Stock Exchange in 2015.

Dermatology technology developer Elastagen has agreed to a $95m acquisition, enabling AmorePacific Ventures to exit the company.

Ping An's corporate venturing unit is looking to raise up to $500m for a dollar fund and $800m for a renminbi fund, both of which will target healthcare investments.

Maryland-based businesses working within the digital health, biohealth and life sciences sectors could receive tailored support on how to capture early sales revenue.

Allergan has acquired Elastagen, a spinout from University of Sydney, for an upfront consideration of $95m and contingent, commercial payments.

Reheal is developing a flexible and transparent polymeric glove that offers an effective wound dressing therapy for hand injuries.

NWS Holdings has contributed to the first close of the mobile health monitoring platform's series A round, which is expected to close at up to $120m.

Spun out from Memorial Sloan Kettering Cancer Center, Paige.ai is developing artificial intelligence technology to improve the clinical diagnosis and treatment of cancer.

Two government-backed vehicles have invested in Manchester Imaging, which will soon launch software to detect early signs of tooth decay.